Social Media Ideas for Competitive Generic Therapy

A $10 Generic Cut LDL Cholesterol by 53%. Why Are Employers Being Pushed Toward $700-a-Month Drugs?

Research from TOWARD Health and collaborating institutions reports LDL reductions nearly three times the conventional ezetimibe response and within the range reported in PCSK9 inhi...

Renova Pharmaceuticals launches its first three generic products

Renova Pharmaceuticals LLC, a Fairfield-based drug company focused on bringing high-quality and affordable generic medicines to patients, announced Sept. 11 the commercial launch o...

FDA Finalizes Rules for Deciding When Generic Drugs Can Substitute for Brand-Name Prescriptions

The U.S. Food and Drug Administration has finalized guidance explaining how it determines whether prescription drug products are therapeutically equivalent—an evaluation that can h...

Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat

GLOBE and MFN Pricing: Implications for Cross-Border Drug Development and Transactions

On Oct. 2, 2026, the Centers for Medicare & Medicaid Services (CMS) published the final rule for the Global Benchmark for Efficient Drug Pricing (GLOBE) Model. GLOBE is a manda...

Medicines Without Competition Now Eat Up Nearly 40% of Italy’s Public Drug Budget

A new Italian Medicines Agency analysis shows that medicines without market competition consumed 9.6 billion euros, or 38.6 percent, of Italy's public pharmaceutical spending in 20...

FDA clears first generic radioligand drug; Sionna turns to layoffs

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early prom...

Genentech, Novartis Sue Amneal Over Bid To Sell Xolair Copy

Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of the...

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

Biosimilars Boast Big Savings But Face IP Risks, Report Says

There are no biosimilar drugs in development for 90% of biologic products set to lose their patent exclusivity by 2034, according to a report released Thursday by the Association f...

<![CDATA[The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals]]>

The Biggest Pharmaceutical Launches in History—and What They Teach Us About Winning in Today’s Market

The Biggest Pharmaceutical Launches in History—and What They Teach Us About Winning in Today’s Market Anonymous (not verified) Wed, 10/21/2026 - 22:16 pharmagather item...

Biogen Must Face Pharmacies' MS Drug Monopoly Suit

An Illinois federal judge on Tuesday refused to dismiss Walgreens and Kroger's lawsuit accusing Biogen Inc. of illegally stifling competition for its multiple sclerosis drug Tecfid...

<![CDATA[The Realistic Path to Making MFN Pricing Permanent]]>

<![CDATA[MFN Raises the Stakes for Japan Launch Pricing]]>

340B Rebate Pilot — The Clock Starts Now

<![CDATA[Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing]]>

<![CDATA[Consistency as a Competitive Advantage in a Changing Market]]>

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don't Qualify

WEDNESDAY, Aug. 26, 2026 — In January, Jeff La Marca got a prescription for the popular weight loss drug Zepbound. But he couldn’t afford the $750 monthly price tag. “I thought, ‘T...